1. Introduction
===============

Celiac disease (CD) is one of the most important malabsorption diseases caused by sensitivity to gluten grains in the small intestine. This disease causes inflammation in the small intestine and it can impede the absorption of nutrients ([@b1-epj-09-3883]). Gluten can be found in cereals such as wheat and barley ([@b2-epj-09-3883]). This disease can occur at any age ([@b1-epj-09-3883]). Celiac disease can cause symptoms such as weight loss, growth retardation, osteoporosis, anemia, classic symptoms of malabsorption, chronic constipation, abdominal pain and metabolic bone diseases in patients ([@b3-epj-09-3883]). Signs of mental illness such as depression and cognitive impairment are variable in this disease ([@b4-epj-09-3883]). There are several ways to diagnose celiac disease and using Anti-Tissue Transglutaminase and duodenal biopsy ([@b1-epj-09-3883]). Various studies around the world have investigated the prevalence of celiac disease. IgA-class tissue transglutaminase antibody test has been used in most of these studies. Prevalence of celiac disease in populations of America and Europe has been reported nearly 1% ([@b5-epj-09-3883]--[@b9-epj-09-3883]). In studies carried out in Finland, Sweden and Mexico based on serology and duodenal biopsy in the general population, the prevalence of celiac disease has been reported about 1% ([@b10-epj-09-3883]--[@b12-epj-09-3883]). Also in studies conducted on different individuals based on serology, prevalence rate has been reported as 0.7% in Italy, and 0.3% in Germany ([@b13-epj-09-3883]). Celiac disease in countries of Eastern Mediterranean Region Organization (EMRO) including North Africa and the Middle East are increasingly on the rise ([@b6-epj-09-3883], [@b14-epj-09-3883]--[@b17-epj-09-3883]). Accordingly, it has imposed a lot of economic costs on the respective countries ([@b18-epj-09-3883]). In some studies, this disease has been diagnosed two to three times more in women than in men ([@b19-epj-09-3883]). However, in studies carried out in the general population, a significant difference was not observed between the prevalence of the disease in both sexes ([@b7-epj-09-3883], [@b9-epj-09-3883]). Increased prevalence of celiac can be due to the high sensitivity of serological tests and more attention to this disease. If just a clinical method is used to diagnose this disease, a large proportion of people may not be diagnosed with the disease ([@b20-epj-09-3883]). Thus, this systematic review and meta-analysis study was conducted to assess the prevalence of celiac disease in Iran. The results may also be helpful in enlightening researchers and policy makers for adopting effective policies and programs to reduce the prevention and prevalence of celiac disease.

2. Material and Methods
=======================

2.1. Search methods
-------------------

To perform this study and find the related studies, Embase, Pub Med, Web of Science, Google Scholar, MagIran, Scientific Information Database (SID) and Iranmedex databases were searched to December 2015. Searching for studies was carried out in two languages of English and Persian. Moreover, conferences related to celiac disease, and the reference lists of studies were also assessed. For finding the related studies, the keywords based on Medical Subject Headings (MeSH) were used and the search strategy in databases was applied according to title and abstract as "Prevalence" OR "Frequency" AND "Celiac Disease" OR "coeliac disease" AND" Iran ".

2.2. Study selection
--------------------

All Iranian population-based studies in which the prevalence of celiac disease has been reported, the studies in which the diagnostic methods including serological tests and a biopsy of the duodenum have been used according to the Marsh classification ([@b21-epj-09-3883]) and those that their results clearly suggest the prevalence of celiac, were selected as inclusion criteria. Moreover, some researches with the following characteristics were excluded from the study:

1.  Case Report, Case Series and Quasi-Experimental studies.

2.  Those which lacked appropriate data for estimating prevalence.

3.  The studies not conducted based on population.

4.  Case Report, Case-Series, Quasi-Experimental and Letter of Editor studies.

5.  The studies not applied standard diagnostic method and those with unclear results.

6.  Those conducted on non-Iranian population.

2.3. Data collection
--------------------

Two authors independently evaluated title and abstract of studies based on inclusion and exclusion criteria. To increase the quality of the studies, blinding method was used and the authors' names and the journal characteristics were hidden. If there is disagreement between the authors about studies, a third person was asked to act as a judge and resolve disagreements with discussion. The agreement between the two authors to extract information was 95.2% and the agreement was 81.5% based on Kappa reliability statistics. After reviewing the studies and finding original studies to analyze, the information contained the name of the first author, year of publication, place of study, the average age in years, the number of positive people by serological test, the number of positive people were extracted by serological test and the number of positive people by duodenal biopsy according to Mesh classification and the type of studies were extracted. All reviews and analyses on literature were conducted based on the PRISMA guidelines.

2.4. Quality assessment of studies
----------------------------------

After finding studies, the STROBE check list ([@b22-epj-09-3883]) was used to assess their quality. According to items of this checklist, the studies that had all the desired items were classified with high quality, those which lacked two of the items with medium quality and those which lacked more than two items were classified as low quality studies. No study with low quality was excluded. The mean score of all studies was 15.75.

2.5. Statistical analysis
-------------------------

In this meta-analysis, the prevalence was calculated based on Der-Simonian/Laird's (DL) test, using random effects model ([@b23-epj-09-3883]). The findings were presented in Forest Plot graph. All data were reported with 95% confidence intervals based on random model. To assess heterogeneity between studies, statistical tests I2 and Q-test ([@b24-epj-09-3883]) were used. P-value of less than 0.05 was considered as statistically significant amount. To explore sources of heterogeneities, variables such as publishing year of studies, geographic area of study, sample size, quality of studies and individuals' age were subject to sub-group analysis. Also, to explore more sources of heterogeneity, some effective factors such as publishing year and participants' age were meta-regressed according to prior defined variables. To assess publication bias, Egger and Begg tests ([@b25-epj-09-3883], [@b26-epj-09-3883]) were used. Studies data were given to the Stata 12.0 software (StataCorp LP, College Station, TX) and analyzed.

3. Results
==========

In the initial search on databases and reference lists search, 520 studies were eligible, of which, 269 studies were duplicate items. According to the survey conducted on the remaining studies, 93 studies were excluded because of lack of relevance on the subject. The full texts of the 158 studies were investigated. Finally, 63 studies were entered to meta-analysis phase ([@b27-epj-09-3883]--[@b89-epj-09-3883]). [Figure (1)](#f1-epj-09-3883){ref-type="fig"} shows PRISMA flowchart of selecting the studies.

3.1. Characteristics of the included studies
--------------------------------------------

The number of participants in these studies was 36,833. Mirzaagha's study of 2,999 participants in Golestan province was the largest, and Najafi's study with 64 participants in Tehran province, was the smallest study. Studies were conducted between years 2003 and 2015. The participants' age in these studies varied between 5--57 years. [Table (1)](#t1-epj-09-3883){ref-type="table"} shows the characteristics of the included studies.

3.2. Quality of studies
-----------------------

After checking quality of included studies based on the STROBE checklist, 25 of them (39.6%) were of high-quality, 22 papers (34.9%) were of average quality and 16 papers (25.5%) were of low quality.

3.3. Prevalence of celiac disease
---------------------------------

The overall prevalence of celiac disease in 63 studies that had used serological tests for the diagnosis, was observed as 3% (95% CI: 0.03--0.03, I2: 90.9%) ([Figure 2](#f2-epj-09-3883){ref-type="fig"}). The number of participants in this study was 36,833. Besides, the overall prevalence of celiac disease in 41 studies that had used biopsy method for diagnosis, was observed as 2% (95% CI: 0.01--0.02, I2: 87.7%) ([Figure 3](#f3-epj-09-3883){ref-type="fig"}). The number of participants in this study was 24,538.

3.4. Results of subgroup analysis
---------------------------------

The pooled prevalence was stratified according to age, sample size, the quality of studies, year of publication, and geographic area of studies in [Table (2)](#t2-epj-09-3883){ref-type="table"}.

3.5. Ages categories and prevalence of celiac disease
-----------------------------------------------------

The prevalence of celiac disease in studies that had used serological tests for the diagnosis was observed as 3% (95% CI: 0.03--0.06) for the age group of less than ten years, 5% (95% CI: 0.03--0.06) for the age group 10 to 20 years, 3% (95% CI: 0.02--0.04) for the age group of 20--30 years, 3% (95% CI: 0.02--0.04) for the age group 30--40 years, 2% (95% CI: 0.03--0.04) for the age group 40--50 years and 4% (95% CI: 0.00--0.04) for the age group 50 to 60 years. The prevalence of celiac disease in studies that had used duodenal biopsy for diagnosis was 2% (95% CI: 0.00--0.04) for the age group less than 10 years, 3% (95% CI: 0.01--0.04) for the age group 10--20 years, 1% (95% CI: 0.01--0.02) for the age group 20--30 years, 2% (95% CI: 0.02--0.03) for the age group 30--40 years, 0% ( 95% CI: −0.01--0.03) for the age group 40--50 years, and 1% ( 95% CI: −0.01--0.03) for the age group 50--60 years.

3.6. Sample size and prevalence of celiac disease
-------------------------------------------------

The prevalence of celiac disease in studies that had used serological tests for the diagnosis was 4% (95% CI: 0.03--0.05) for studies with the sample size less than 800 participants, 3% (95% CI: 0.02--0.04) for studies with 800 to 1,600 participants, 2% (95% CI: −0.01--0.06) for studies with 1,600 and 2,400 participants, and 1% (95% CI: 0.00--0.02) for studies with more than 2,400 participants. Prevalence of celiac disease in studies that had used the duodenal biopsy for diagnosis was 3% (95% CI: 0.03--0.04) in sample sizes less than 800 participants, 0% (95% CI: 0.00--0.01) for studies with 800--1,600 participants, 1% (95% CI: −0.00--0.01) for studies with 1,600--2,400 participants and 1 % (95% CI: 0.01--0.02) for studies with more than 2,400 participants.

3.7. Quality of the studies included and prevalence of celiac disease
---------------------------------------------------------------------

The prevalence of celiac disease was observed for high-quality studies that had used serological tests for diagnosis as 3% (95% CI: 0.02--0.04), for studies of medium quality, 5% (95% CI: 0.04--0.07) and for low quality studies, 2% (95% CI: 0.01--0.02). Prevalence of celiac disease in high-quality studies that had used the duodenal biopsy for diagnosis was 3% (95% CI: 0.02--0.03), for studies of medium quality, 1% (95% CI: 0.01--0.01) and for poor quality studies, 4% (95% CI: 0.02--0.06).

3.8. Publication of year studies included and prevalence of celiac disease
--------------------------------------------------------------------------

The prevalence of celiac disease in studies that had used serological tests for diagnosis and published in the years 2003--2007 was observed as 1% (95% CI: 0.01--0.02) in the years 2007--2011, 3% (95% CI: 0.02--0.04) for the years 2011--2015 and 4% (95% CI: 0.03--0.05) in the years 2011--2015. The prevalence of celiac disease in studies that had used the duodenal biopsy for diagnosis and published was 1% (95% CI: 0.01--0.01) in 2003--2007, 2% (95% CI: 0.01--0.02) for the years 2007 to 2011, and 3% (95% CI: 0.02--0.04) for the years 2011--2015.

3.9. Geographical background and prevalence of celiac disease
-------------------------------------------------------------

The prevalence of celiac disease was 3% (95% CI: 0.02--0.04) in studies that had used serological tests for the diagnosis and were carried out in central Iran, 1% (95% CI: 0.00--0.01) for studies conducted in northern Iran, 2% (95% CI: 0.01--0.03) for studies conducted in the south. 5% (95% CI: 0.0--0.07) for studies conducted in West region of Iran and 4% (95% CI: 0.02--0.05) for studies conducted in eastern regions. The prevalence of celiac disease was 2% (95% CI: 0.02--0.03) in studies that had used the duodenal biopsy for diagnosis, 1% (95% CI: 0.00--0.01) for studies conducted in central Iran, 1% (95% CI: 0.00--0.01) for studies carried out in northern Iran, 1% (95% CI:0.00--0.01) for studies conducted in the south, 5% (95% CI: 0.03--0.08) for studies conducted in West region and 2% (95% CI: 0.01--0.03) for studies performed in the eastern regions.

3.10. Publication bias
----------------------

The results of the assessment of publication bias were observed in the studies that had used serological tests for the diagnosis, and were observed for the tests Begg = 0.000, Egger = 0.000, and for studies that had used duodenal biopsy for the diagnosis, Begg = 0.001, Egger = 0.000. The results suggest that publication bias has occurred.

3.11. Sensitivity analysis
--------------------------

To ensure strong results, we excluded Mirzaagha's study and conducted sensitivity analysis. For studies that had used serological tests, the prevalence remained unchanged and only CI 95%, 3% (95% CI: 0.03--0.04) changed. For studies that had used the duodenal biopsy, no change was created in prevalence. Hence exclusion of this study did not have much effect on the results.

3.12. Results of meta-regression
--------------------------------

Meta-regression results are shown in [Table (3)](#t3-epj-09-3883){ref-type="table"}. Meta-regression for studies that had used serological tests showed that the prevalence of celiac disease increases based on the publishing year of studies, decreases based on participants' age, and increases based on a sample size of studies. But none are statistically significant. Meta-regression for studies that had used the duodenal biopsy, reduced based on the participants, age, and none were significant, but significantly increased based on sample size.

3.13. Results of cumulative meta-analysis
-----------------------------------------

For cumulative meta-analysis, studies and samples were ranked according to year of publication. Prevalence was declining for studies that used serological tests, when they were ranked according to year of publication and sample size. For studies that used duodenal biopsy, a decreasing prevalence was observed when studies were ranked according to year of publication and sample size.

4. Discussion
=============

This study is the first systematic review and meta-analysis of celiac disease in Iran. The prevalence of celiac disease in different parts of Iran was studied. The results showed that the prevalence was 3% (95% CI: 0.03--0.03) for studies which used serological methods for diagnosis and 2% (95% CI: 0.01 -- 0.02), for those used biopsy method for diagnosis. The prevalence of celiac disease was 0.71% in a study carried out in America ([@b90-epj-09-3883]) based on serological tests and 1.5% in Finland on the basis of conducted serological tests ([@b91-epj-09-3883]). In another study in Saudi Arabia ([@b92-epj-09-3883]), the prevalence rate was 3% and 1% respectively on the basis of serological tests and biopsy method. The results show that the prevalence of celiac disease in Iran is more than in developed countries and is almost identical to the developing countries. Differences in the prevalence difference, between developed and developing countries, may be due to ideal health status, better servicing, and more advanced medical equipment in developed countries. The difference observed between the prevalence of serological tests and a biopsy method in the present study, is often due to lack of proper and accurate use of biopsy for the diagnosis of celiac disease in the developing countries ([@b93-epj-09-3883]). Unfortunately, in many cases, the diagnosis of celiac disease is solely based on serological tests. Factors such as intestinal parasitic and bacterial infections and malnutrition can cause changes in intestinal tissue similar to celiac disease characteristics. This could be the reason for the high prevalence of celiac disease in studies that have used serological tests. Our results showed that the lack of cohesion in the diagnostic criteria for celiac disease could be one reason for heterogeneity among studies based on p-value of Chi-square Test and I2. Additionally, high heterogeneity observed in this study may be due to the high number of studies and their sample size. Dietary habits can play an important role in the increased prevalence of celiac disease in respective countries. In the Iranian people's diet, grain and especially "Wheat", is widely consumed and this is an important factor for the increase in celiac disease. Celiac disease is rising not only in developed countries but in developing regions such as the Middle East, South Asia, North East, West Africa, and South America where taking a diet of grains, especially wheat, is common ([@b94-epj-09-3883]). Serologic tests are required in Iran for screening groups at risk to identify the disease. The prevalence of celiac disease is in all age groups up to 20 years. Given that traditional methods for breastfeeding and prolonged feeding with this practice and not cutting it at the right time is responsible for mild symptoms in these patients, these eating habits create a protecting effect for gluten intolerance in these individuals and a factor for more difficult reorganization of celiac disease ([@b95-epj-09-3883]). According to the study results, the prevalence of celiac disease is more common in the central and western regions of Iran. The high prevalence of celiac disease in these areas is because of the great city of Tehran. High population density, wrong eating habits, different ethnicities, population access to diagnostic centers of this disease can cause high prevalence in central Iran. Moreover, the prevalence of celiac disease is very high in Western Iran. Wheat consumption in these areas is very high. In the present study, some limitations were observed which can be referred as follows: 1) High heterogeneity was observed due to variety of diagnostic methods of patients in studies, this factor can influence the results, 2) The studies data were not possible for investigating the prevalence of celiac disease in terms of gender, 3) Only 36.9% of studies were of high-quality, which can be a cause for bias, 4) In some studies, only a diagnostic method had been used, 5) Carrying a large number of studies in Tehran also could be a factor affecting the bias, 6) The various diseases in people in some studies could also be another factor to influence the results. In conclusion, data from our meta-analysis confirmed higher serological tests for the diagnosis compared to biopsy method for diagnosis celiac disease. Further studies regarding the entire Iranian population and compared serological tests and biopsy method are needed to validate diagnosis celiac disease.

5. Conclusions
==============

In conclusion, celiac disease in Iran has an estimated prevalence that was 3% (95% CI: 0.03--0.03) for studies which used serological methods for diagnosis and 2% (95% CI: 0.01 -- 0.02) for those which used biopsy method for diagnosis. The prevalence of celiac disease in Iran was similar or even higher than that reported world-wide.
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###### 

Characteristics of studies included

  Athur             Year   City            Age     Sample size   Type of study     Quality of study
  ----------------- ------ --------------- ------- ------------- ----------------- ------------------
  Shahbazkhania     2003   Tehran          35.5    2000          Cross-sectional   Intermediate
  Shahbazkhani      2004   Tehran          18.7    250           Cross-sectional   Low
  Shahbazkhania     2004   Tehran          31      100           Cross-sectional   High
  Ale Yasin         2004   Tehran          29.55   250           Case-control      Intermediate
  Tirgar-Fakheri    2004   Sari            35.5    1438          Cross-sectional   Intermediate
  Farahmand         2004   Tehran          13.9    35            Cross-sectional   Intermediate
  Nikpour           2005   Tehran          39      400           Cross-sectional   Intermediate
  Khoshnia          2005   Gonbad-Kavoos   50      1209          Cross-sectional   Intermediate
  Sheikholeslami    2005   Ghazvin         31.87   120           Case-control      Intermediate
  Akbari            2006   Kerman-Sari     33.7    2799          Cross-sectional   Intermediate
  Joshaghani        2006   Golestan        30      2547          Cross-sectional   Intermediate
  Masoodi           2007   Bandar Abbas    36.7    150           Cross-sectional   High
  Nikpour           2007   Tehran          40.3    126           Prospective       Low
  Sharifi           2008   Tabriz          25.35   250           Case-control      Intermediate
  Saberi-Firouzi    2008   Shiraz          45.3    1440          Cross-sectional   Intermediate
  Hashemi           2008   Ahwaz           16.8    104           Cross-sectional   High
  Dehghani          2008   Shiraz          9.8     72            Cross-sectional   High
  Emami             2008   Tehran          35.3    270           Cross-sectional   Low
  khoshbaten        2008   Tabriz          25.35   250           Case-control      Intermediate
  Zamani            2009   Tehran          36.7    288           Cross-sectional   High
  Rostami-Nejad     2009   Tehran          36      411           Cross-sectional   High
  Ghahramani        2009   Arak            40      810           Case-control      Low
  khoshbaten        2009   Tabriz          37      300           Cross-sectional   Low
  Bahari            2010   Zahedan         33.2    1600          Cross-sectional   High
  Keshavarz         2010   Kermanshah      31      170           Cross-sectional   Intermediate
  Ghergherehchi     2010   Tabriz          9.05    135           Cross-sectional   Low
  Mirzaagha         2010   Tehran          36.5    2999          Cross-sectional   High
  Sima              2010   Tehran          33.7    112           Cross-sectional   Low
  Shahbazkhani      2010   Tehran          39.79   100           Cross-sectional   Low
  Farahmand         2011   Tehran          7.18    301           Cross-sectional   High
  Rahimi            2011   Tehran          40.56   316           Cross-sectional   High
  Norouzinia        2011   Tehran          26      796           Cross-sectional   Intermediate
  Rostami-Nejad     2011   Tehran          36.1    407           Cross-sectional   Low
  Bashiri           2011   Kermanshah      18      241           Cross-sectional   High
  Inaloo            2011   Shiraz          10.6    1600          Case-control      Intermediate
  Akhondi-Meybodi   2011   Yazd            29.85   125           Cross-sectional   Low
  Farahmand         2012   Tehran          12.8    634           Cross-sectional   High
  Bakhshipour       2012   Zahedan         37.4    364           Cross-sectional   High
  Emami             2012   Isfahan         34.3    324           Case-control      Intermediate
  Mehrdad           2012   Rasht           39.46   454           Cross-sectional   Low
  Khoshbaten        2012   Tabriz          37      200           Cross-sectional   High
  VosoghiniaH       2012   Mashhad         19.78   87            Cross-sectional   Intermediate
  Bakhshipour       2013   Zahedan         37.4    403           Cross-sectional   High
  Amini-Ranjbar     2013   Kerman          6       144           Cross-sectional   High
  Dehghani          2013   Shiraz          9.5     1500          Cross-sectional   High
  Houshiyar         2013   Ardabil         31.4    105           Cross-sectional   Low
  Jafarihaydarlo    2013   Ilam            29.02   1000          Cross-sectional   Low
  Hayatbakhsh       2013   kerman          43      2259          Cross-sectional   Intermediate
  Shaykhesmaili     2013   Sanandaj        35.45   180           Case-control      Low
  Ghergherehchi1    2013   Tabriz          12      200           Cross-sectional   Intermediate
  Mahmoodi          2014   Ilam            29.02   1000          Cross-sectional   High
  Shayesteh         2014   Ahvaz           31.8    465           Cross-sectional   High
  Najafi            2014   Tehran          8.39    64            Cross-sectional   High
  Zahmatkeshan      2014   Shiraz          5.73    82            Case-control      Intermediate
  Honar             2014   Shiraz          12.7    215           Case-control      Low
  Yazdanbod         2014   Ardabil         28.45   181           Cross-sectional   Intermediate
  Honar             2015   Shiraz          10.38   83            Prospective       High
  Fallahi           2015   Tehran          12      96            Cross-sectional   Low
  Ahmadi            2015   kerman          34.57   143           Cross-sectional   High
  Dehghani          2015   Shiraz          57.68   101           Cross-sectional   Intermediate
  Shahramian        2015   Zahedan         43.09   1002          Case-control      High
  Jandaghi          2015   Tehran          35.03   406           Case-control      High
  Shahramian        2015   Zabol-Zahedan   28.81   620           Case-control      High

###### 

Results of subgroup analysis

  Variables                Serological tests   Marsh                                                        
  ------------------------ ------------------- --------- -------- ------- ------ --------- -------- ------- ------
  Age (year)               \<10                3%        1%--4%   0.000   60.5   2%        0%--4%   0.012   74.4
  10--20                   5%                  3%--6%    0.000    86.4    3%     1%--4%    0.000    87.2    
  20--30                   3%                  2%--4%    0.000    93.0    1%     1%--2%    0.000    0.0     
  30--40                   3%                  3%4%      0.000    91.7    2%     2%--3%    0.000    90.3    
  40--50                   2%                  1%--4%    0.003    95.8    0%     0%--1%    0.003    0.0     
  50--60                   4%                  0%--4%    0.041    \-      1%     −1%--3%   0.315    \-      
  Sample size              \<800               4%        3%--5%   0.000   85.7   3%        3%--4%   0.000   82.0
  800--1600                3%                  2%--4%    0.000    96.0    0%     0%--1%    0.002    73.3    
  1600--2400               2%                  −1%--6%   0.191    98.5    1%     0%--1%    0.001    \-      
  \>2400                   1%                  0%--2%    0.008    93.0    1%     1%--2%    0.000    71.0    
  Quality of the studies   High                3%        2%--4%   0.000   91.3   3%        2%--3%   0.000   90.0
  intermediate             5%                  4%--7%    0.000    88.1    1%     1%--1%    0.000    85.8    
  Low                      2%                  1%--2%    0.000    88.1    4%     2%--6%    0.000    83.5    
  Year of publication      2003--2007          1%        1%--2%   0.000   81.8   1%        1%--1%   0.000   73.9
  2007--2011               3%                  2%--4%    0.000    90.0    2%     1%--2%    0.000    91.5    
  2011--2015               4%                  3%--5%    0.000    81.8    3%     2%--4%    0.000    73.9    
  Regional background      Central             3%        2%--4%   0.000   88.3   2%        2%--3%   0.000   81.8
  North                    1%                  0%--1%    0.001    76.1    1%     0%--1%    0.004    46.0    
  South                    2%                  1%--3%    0.000    84.3    1%     0%--1%    0.003    83.8    
  West                     5%                  4%--7%    0.000    89.9    5%     3%--8%    0.000    85.0    
  East                     4%                  2%--5%    0.000    94.9    2%     1%--3%    0.000    91.0    

###### 

Results meta-regression analysis

  Items         Serological tests   Marsh                                                                         
  ------------- ------------------- ------- ------ ------- ------- ------- ------- ------ ------- ------- ------- -------
  Year          −0.00               −0.11   0.34   0.95    0.00    0.00    0.00    0.00   0.60    0.55    −0.00   0.00
  Age           −0.00               −0.00   0.86   0.17    0.00    0.00    −0.00   0.00   −0.20   0.83    −.000   0.00
  Sample size   −2.28               −.000   0.02   −2.36   −6.41   0.00    −0.00   5.04   −2.90   0.00    −.000   −4.38
  Cons          3.01                −8.25   0.35   −0.93   2.81    −2.62   −1.35   2.32   −0.58   −0.56   −6.05   3.35
